Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1
暂无分享,去创建一个
G. Dore | M. Weltman | G. McCaughan | D. Crawford | S. Roberts | W. Rawlinson | W. Cheng | W. Sievert | B. Rizkalla | J. Depamphilis | Motoko Yoshihara | M. Yoshihara | Jean K. DePamphilis
[1] William M. Lee,et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. , 2010, Gastroenterology.
[2] G. Dore,et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. , 2010, Journal of hepatology.
[3] R. MAC NICHOLAS,et al. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G‐CSF and novel agents , 2010, Alimentary pharmacology & therapeutics.
[4] Jacques Fellay,et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C , 2010, Nature.
[5] G. Dore,et al. Impact of high‐dose peginterferon alfa‐2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial , 2009, Hepatology.
[6] Jacques Fellay,et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.
[7] E. Snoeck,et al. Pharmacokinetics of ribavirin in patients with hepatitis C virus. , 2006, British journal of clinical pharmacology.
[8] P. Portincasa,et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. , 2006, Current medicinal chemistry.
[9] H. Nomura,et al. Factors contributing to ribavirin‐induced anemia , 2004, Journal of gastroenterology and hepatology.
[10] R. Gish,et al. Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection , 2004, Journal of viral hepatitis.
[11] A. Bruchfeld,et al. Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis , 2002, Therapeutic drug monitoring.
[12] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[13] P. Marcellin,et al. Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C , 2005, Clinical pharmacokinetics.